EP1009432A4 - Zusammensetzungen und methoden zur hemmung von transplantatabstossung und anderen gegen die annahme gerichteten von t-lymphozyten vermittelten immunantworten - Google Patents

Zusammensetzungen und methoden zur hemmung von transplantatabstossung und anderen gegen die annahme gerichteten von t-lymphozyten vermittelten immunantworten

Info

Publication number
EP1009432A4
EP1009432A4 EP98930097A EP98930097A EP1009432A4 EP 1009432 A4 EP1009432 A4 EP 1009432A4 EP 98930097 A EP98930097 A EP 98930097A EP 98930097 A EP98930097 A EP 98930097A EP 1009432 A4 EP1009432 A4 EP 1009432A4
Authority
EP
European Patent Office
Prior art keywords
adaptive
composition
immune responses
preventing graft
lymphocyte immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP98930097A
Other languages
English (en)
French (fr)
Other versions
EP1009432A1 (de
Inventor
David M Harlan
Alan D Kirk
Stuart J Knechtle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United States Department of the Navy
Wisconsin Alumni Research Foundation
Original Assignee
United States Department of the Navy
Wisconsin Alumni Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Department of the Navy, Wisconsin Alumni Research Foundation filed Critical United States Department of the Navy
Publication of EP1009432A1 publication Critical patent/EP1009432A1/de
Publication of EP1009432A4 publication Critical patent/EP1009432A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP98930097A 1997-06-11 1998-06-10 Zusammensetzungen und methoden zur hemmung von transplantatabstossung und anderen gegen die annahme gerichteten von t-lymphozyten vermittelten immunantworten Withdrawn EP1009432A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4938997P 1997-06-11 1997-06-11
US49389P 1997-06-11
PCT/US1998/011910 WO1998056417A1 (en) 1997-06-11 1998-06-10 Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses

Publications (2)

Publication Number Publication Date
EP1009432A1 EP1009432A1 (de) 2000-06-21
EP1009432A4 true EP1009432A4 (de) 2004-07-07

Family

ID=21959563

Family Applications (1)

Application Number Title Priority Date Filing Date
EP98930097A Withdrawn EP1009432A4 (de) 1997-06-11 1998-06-10 Zusammensetzungen und methoden zur hemmung von transplantatabstossung und anderen gegen die annahme gerichteten von t-lymphozyten vermittelten immunantworten

Country Status (6)

Country Link
EP (1) EP1009432A4 (de)
JP (1) JP2002504120A (de)
AU (1) AU748533B2 (de)
CA (1) CA2291338A1 (de)
IL (1) IL133070A0 (de)
WO (1) WO1998056417A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
CA2357035A1 (en) * 1998-12-29 2000-07-06 University Of Vermont And State Agricultural College Use of cd40 engagement to alter t cell receptor usage
ES2286006T3 (es) * 1999-01-08 2007-12-01 Wisconsin Alumni Research Foundation Prevencion del rechazo cronico a transplante mediante combinacion de inmunotoxinas y bloqueadores de la coestimulacion.
AU2001233027A1 (en) 2000-01-27 2001-08-07 Genetics Institute, Llc Antibodies against ctla4 (cd152), conjugates comprising same, and uses thereof
EP1284747A2 (de) 2000-05-12 2003-02-26 Beth Israel Deaconess Medical Center, Inc. Zusammensetzungen und verfahren zur erzielung einer immunsuppression
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
MXPA02012157A (es) * 2000-06-09 2003-06-06 Bristol Myers Squibb Co Metodos para regular una respuesta inmune mediada por celulas al bloquear se°ales linfociticas y al bloquear la adhesion mediada por el antigeno 1 asociado con la funcion de linfocitos.
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
CA2630062C (en) 2000-07-03 2014-10-14 Bristol-Myers Squibb Company Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule
CA2436180C (en) * 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20050101012A1 (en) 2001-03-12 2005-05-12 Gerold Schuler CD4+CD25+ regulatory T cells from human blood
EP1241249A1 (de) * 2001-03-12 2002-09-18 Gerold Schuler Regulatorische CD4+CD25+ T Zellen aus menschlichem Blut
ATE390931T1 (de) 2001-05-23 2008-04-15 Bristol Myers Squibb Co Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen
US8222033B2 (en) 2002-08-12 2012-07-17 Argos Therapeutics, Inc. CD4+CD25− T cells and Tr1-like regulatory T cells
GB0815788D0 (en) * 2008-08-29 2008-10-08 Isis Innovation Therapeutic antibodies
TWI832868B (zh) 2018-06-22 2024-02-21 日商順天生化股份有限公司 用於誘發感染性免疫耐受之組合物
AU2019288683A1 (en) 2018-06-22 2021-01-21 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
US12139537B2 (en) 2018-06-22 2024-11-12 Junten Bio Co., Ltd. Antibody inducing immune tolerance, induced lymphocyte, and cell therapy agent therapeutic method using induced lymphocyte
JP2025038261A (ja) * 2022-02-08 2025-03-19 学校法人順天堂 他家移植方法及び拒絶反応抑制方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2191733A1 (en) * 1994-06-07 1995-12-21 Daniel A. Vallera Methods for inhibiting antigen specific t cell responses

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997034633A1 (en) * 1996-03-20 1997-09-25 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ELWOOD E T ET AL: "LONG-TERM MURINE SKIN ALLOGRAFT SURVIVAL WITH PERIOPERATIVE CTLA4-IG AND ANTI-GP39: THE ROLE OF CD4+ T CELL.S", SURGICAL FORUM, CHICAGO, US, vol. 47, 1996, pages 427 - 429, XP002037031, ISSN: 0071-8041 *
GRIGGS N D ET AL: "THE RELATIVE CONTRIBUTION OF THE CD28 AND GP39 COSTIMULATORY PATHWAYS IN THE CLONAL EXPANSION AND PATHOGENIC ACQUISITION OF SELF-REACTIVE T-CELLS", JOURNAL OF EXPERIMENTAL MEDICINE, TOKYO, JP, vol. 183, no. 3, 1 March 1996 (1996-03-01), pages 801 - 810, XP002043672, ISSN: 0022-1007 *
LARSEN C P ET AL: "LONG-TERM ACCEPTANCE OF SKIN AND CARDIAC ALLOGRAFTS AFTER BLOCKING CD40 AND CD28 PATHWAYS", NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 381, no. 6581, 30 May 1996 (1996-05-30), pages 434 - 438, XP002037035, ISSN: 0028-0836 *
SCHAUB M ET AL: "SYNERGISTIC EFFECT OF CD-40L/CD40 AND CD28/B7 BLOCKADE IN MURINE EAE", JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, MOSBY - YEARLY BOOK, INC, US, vol. 99, no. 1, PART 2, 1997, pages S206, XP002037033, ISSN: 0091-6749 *
See also references of WO9856417A1 *

Also Published As

Publication number Publication date
IL133070A0 (en) 2001-03-19
EP1009432A1 (de) 2000-06-21
AU748533B2 (en) 2002-06-06
AU7956798A (en) 1998-12-30
CA2291338A1 (en) 1998-12-17
WO1998056417A1 (en) 1998-12-17
JP2002504120A (ja) 2002-02-05

Similar Documents

Publication Publication Date Title
AU4922785A (en) Method for separating bovine lactoferrin from cow's milk and purifying same
FR2739041B1 (fr) Procede de nettoyage et d'assainissement de surfaces solides ou d'installations industrielles
EP0949982A4 (de) Verbessertes verfahren und vorrichtung zur herstellung von teilchenförmigen oder festen körpern
EP0862564A4 (de) Photoaktivierbare verbindungen aus prevention des intimalen hyperplasie und anderen krankheiten
EP0709467A3 (de) Zusammensetzungen und Verfahren für die Detektion von Chlamydia Trachomatis
DZ1958A1 (fr) Composés inhibiteurs de l'enzyme l-lpa compositionpharmaceutiques les composant et procédés pour leur préparation.
BR9300586A (pt) Aparelho refinador apropriado para ser usado no processamento de sucos
EP0886471A4 (de) Verfahren und zusammensetzungen zur induzierung oraler toleranz in saugetieren
AU2945795A (en) DNA encoding an 18 Kd CDK6 inhibiting protein
ZA9511015B (en) Composition modulandt l'apoptase comprenant un facteur influencant le taux intracellulaire de methional ou de malondialdehyde
IL133070A0 (en) Composition and method to prevent graft rejection and other counter-adaptive t lymphocyte mediated immune responses
ITBO960254A0 (it) Metodo ed unita' per l'ordinamento di prodotti
IL102725A0 (en) Method for identifying and enumerating lymphocytes
EP0924985A4 (de) Verfahren zur inhibierung der fas-expression
EP0853890A4 (de) Lactose-enthaltende nahrungsmittelzusammensetzung für kinder
EP0707022A3 (de) Methode zur Darstellung von Arylen-Vinylen-Polymeren und diese enthaltende elektrolumineszente Vorrichtung
HU9602274D0 (en) Detergent composition containing graft copolymer
EP0749988A3 (de) Verfahren zur Herstellung von Cycloolefincopolymeren
GB9100885D0 (en) Method for refining titanium
EP0803579A4 (de) Verfahren und vorrichtung zur vakuumraffination von metallen
FR2742084B1 (fr) Procede et dispositif d'usinage electrochimique de pieces en serie
GB9503436D0 (en) Dielectrophoresis
FR2715280B1 (fr) Latte de renfort et de soutien pour articles d'ameublement ou autres types de sièges.
FR2665850B1 (fr) Machine de nettoyage in situ de rampes d'abreuvoirs suspendues.
EP0712206A3 (de) Treibersystem für abschaltbare Thyristoren

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19991213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20040525

RIC1 Information provided on ipc code assigned before grant

Ipc: 7A 61P 37/08 B

Ipc: 7A 61P 37/06 B

Ipc: 7C 07K 16/28 B

Ipc: 7C 07K 16/00 B

Ipc: 7A 61K 39/395 A

17Q First examination report despatched

Effective date: 20041201

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20050412